Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.48 |
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | POLR1A | O95602 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 1/20 | 0.43 |
| ▸ | FAP | Q12884 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8586635 | 0.82 | BACE1 (0.48) | SLC6A3SLC6A2SLC6A4DHFRLMNA | |
| SCHEMBL3538639 | 0.82 | SLC6A9 (0.56) | SLC6A3SLC6A2SLC6A4DHFRLMNA | |
| SCHEMBL8585666 | 0.79 | CTSL (0.45) | SLC6A3SLC6A2SLC6A4DHFRLMNA | |
| SCHEMBL8587573 | 0.79 | CTSL (0.45) | SLC6A3SLC6A2SLC6A4DHFRLMNA | |
| SCHEMBL8586638 | 0.79 | CTSL (0.45) | SLC6A3SLC6A2SLC6A4DHFRLMNA | |
| SCHEMBL8585664 | 0.79 | CTSL (0.45) | SLC6A3SLC6A2SLC6A4DHFRLMNA | |
| SCHEMBL1798157 | 0.78 | SLC6A9 (0.61) | SLC6A3SLC6A2SLC6A4DHFRLMNA | |
| SCHEMBL3538359 | 0.77 | SLC6A9 (0.60) | SLC6A3SLC6A2SLC6A4DHFRLMNA | |
| SCHEMBL27632140 | 0.77 | POLR1A (0.39) | POLR1ABACE1 | |
| SCHEMBL11240149 | 0.76 | SLC6A3 (0.38) | SLC6A3SLC6A2SLC6A4DHFRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714019-B2 | Indole, azaindole and related heterocyclic pyrrolidine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090186933-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2009-07-23 | — | — | US | disclosed |
| US-7531552-B2 | Indole, azaindole and related heterocyclic pyrrolidine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1474135-B9 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080096912-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-24 | — | — | US | disclosed |
| EP-1474135-B1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060287531-A1 | Indole, azaindole and related heterocyclic pyrrolidine derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2006-12-21 | — | — | US | disclosed |
| EP-1474135-A4 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1474135-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20030236277-A1 | Indole, azaindole and related heterocyclic pyrrolidine derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2003-12-25 | — | — | US | disclosed |
| WO-2003068221-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-21 | — | — | WO | disclosed |
| WO-1998039295-A1 | (R)N-(1-CYCLOPROPYLMETHYLPYRROLIDIN-2-YLMETHYL)BENZAMIDE AND ITS USE AS AN ANTIDIARRHOEAL | JOUVEINAL (FR) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096912-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | IDO1, IDO2, INMT | SLC6A3 691/4885SLC6A2 563/4885SLC6A4 372/4885 |
| US-20090186933-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | IDO1, IDO2, INMT | SLC6A3 691/4885SLC6A2 563/4885SLC6A4 372/4885 |
| US-20060287531-A1 | Indole, azaindole and related heterocyclic pyrrolidine derivatives | IDO1, IDO2, INMT | SLC6A3 691/4885SLC6A2 563/4885SLC6A4 372/4885 |
| US-20030236277-A1 | Indole, azaindole and related heterocyclic pyrrolidine derivatives | IDO1, IDO2, INMT | SLC6A3 691/4885SLC6A2 563/4885SLC6A4 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.